On January 5, 2018 Johnson Co. announced their planned acquisition of Smith Co. The following is a summary of the consideration to be paid for the acquisition. Cash: $10 million Stock: 1 million shares of Johnson Co. common stock. At January 5 the market price of the stock was $20 per share, but as of the date the transaction closed, Johnson Co. stock was trading at $25 per share. Contingent Consideration: The selling shareholders of Smith Co. are entitled to receive $2 million upon receipt of FDA approval (by December 31, 2018) of a medical device Smith is developing that is under review by the FDA. FDA approval is the sole contingency which must be resolved for the contingent consideration to be paid, however if approval is not received by the deadline, no payment is due. As of the acquisition date, Johnson believes there is 80% likelihood the contingent consideration will be paid. 1. What is the amount of consideration used to record this business combination under IFRS? Under US GAAP? 2. At December 31, 2018 the FDA has not granted approval of the medical device, what entry is recorded by Johnson related to the contingent consideration using IFRS? Using US GAAP?

Intermediate Accounting: Reporting And Analysis
3rd Edition
ISBN:9781337788281
Author:James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:James M. Wahlen, Jefferson P. Jones, Donald Pagach
Chapter13: Investments And Long-term Receivables
Section: Chapter Questions
Problem 19E
icon
Related questions
Question
On January 5, 2018 Johnson Co. announced their planned acquisition of Smith Co. The following is a
summary of the consideration to be paid for the acquisition.
Cash: $10 million
Stock: 1 million shares of Johnson Co. common stock. At January 5 the market price of the
stock was $20 per share, but as of the date the transaction closed, Johnson Co. stock was
trading at $25 per share.
Contingent Consideration: The selling shareholders of Smith Co. are entitled to receive $2
million upon receipt of FDA approval (by December 31, 2018) of a medical device Smith is
developing that is under review by the FDA. FDA approval is the sole contingency which must
be resolved for the contingent consideration to be paid, however if approval is not received by
the deadline, no payment is due. As of the acquisition date, Johnson believes there is 80%
likelihood the contingent consideration will be paid.
1. What is the amount of consideration used to record this business combination under IFRS?
Under US GAAP?
2. At December 31, 2018 the FDA has not granted approval of the medical device, what entry is
recorded by Johnson related to the contingent consideration using IFRS? Using US GAAP?
Transcribed Image Text:On January 5, 2018 Johnson Co. announced their planned acquisition of Smith Co. The following is a summary of the consideration to be paid for the acquisition. Cash: $10 million Stock: 1 million shares of Johnson Co. common stock. At January 5 the market price of the stock was $20 per share, but as of the date the transaction closed, Johnson Co. stock was trading at $25 per share. Contingent Consideration: The selling shareholders of Smith Co. are entitled to receive $2 million upon receipt of FDA approval (by December 31, 2018) of a medical device Smith is developing that is under review by the FDA. FDA approval is the sole contingency which must be resolved for the contingent consideration to be paid, however if approval is not received by the deadline, no payment is due. As of the acquisition date, Johnson believes there is 80% likelihood the contingent consideration will be paid. 1. What is the amount of consideration used to record this business combination under IFRS? Under US GAAP? 2. At December 31, 2018 the FDA has not granted approval of the medical device, what entry is recorded by Johnson related to the contingent consideration using IFRS? Using US GAAP?
Expert Solution
steps

Step by step

Solved in 2 steps with 1 images

Blurred answer
Knowledge Booster
Accounting for Employee Compensations and Benefits
Learn more about
Need a deep-dive on the concept behind this application? Look no further. Learn more about this topic, accounting and related others by exploring similar questions and additional content below.
Similar questions
  • SEE MORE QUESTIONS
Recommended textbooks for you
Intermediate Accounting: Reporting And Analysis
Intermediate Accounting: Reporting And Analysis
Accounting
ISBN:
9781337788281
Author:
James M. Wahlen, Jefferson P. Jones, Donald Pagach
Publisher:
Cengage Learning
Financial Reporting, Financial Statement Analysis…
Financial Reporting, Financial Statement Analysis…
Finance
ISBN:
9781285190907
Author:
James M. Wahlen, Stephen P. Baginski, Mark Bradshaw
Publisher:
Cengage Learning
Financial Accounting
Financial Accounting
Accounting
ISBN:
9781305088436
Author:
Carl Warren, Jim Reeve, Jonathan Duchac
Publisher:
Cengage Learning